Estrovera is a dietary supplement made by Metagenics, designed to relieve hot flashes and other menopause symptoms. It contains a single active ingredient: a standardized extract of Siberian rhubarb root called ERr 731, delivered in a small 4 mg tablet taken once daily. Unlike hormone replacement therapy, Estrovera is sold over the counter as a supplement, meaning it has not been evaluated or approved by the FDA to treat any medical condition.
What’s in It
The sole active ingredient is ERr 731, a specific extract of the root of Rheum rhaponticum, commonly known as Siberian rhubarb or rhapontic rhubarb. This is not the same plant as culinary rhubarb (Rheum rhabarbarum) that you’d find in a pie. Siberian rhubarb has a long history of use in traditional European herbal medicine for gynecological complaints.
The active compounds in ERr 731 are hydroxystilbenes, primarily two molecules called rhaponticin and desoxyrhaponticin. These are structurally similar enough to estrogen that they can interact with estrogen receptors in the body, but they do so in a highly selective way that distinguishes them from actual estrogen or conventional hormone therapy.
How It Works in the Body
Your body has two types of estrogen receptors: alpha and beta. They’re found in different tissues and trigger different effects. Estrogen receptor alpha is the one primarily active in breast tissue and the uterine lining, which is why stimulating it raises concerns about cancer risk. Estrogen receptor beta plays a larger role in the brain, bones, and cardiovascular system, and is thought to mediate the temperature-regulating functions that go haywire during menopause.
ERr 731 selectively activates estrogen receptor beta without switching on estrogen receptor alpha. Lab studies using human cells found that at effective concentrations, ERr 731 produced zero activation of the alpha receptor and no anti-estrogenic effect either. It essentially ignores that receptor entirely. At the same concentration, it activated the beta receptor at a level comparable to the body’s own estrogen. When researchers blocked estrogen receptors entirely with a pharmaceutical antagonist, all of ERr 731’s effects disappeared, confirming the activity is genuinely receptor-mediated rather than some unrelated mechanism.
This selectivity is the core of the product’s appeal. The idea is that it can help with hot flashes and mood changes (beta receptor territory) without stimulating breast tissue or the uterine lining (alpha receptor territory).
What It’s Used For
Estrovera is marketed specifically for perimenopause and menopause symptom relief. The primary symptom it targets is hot flashes, but users and practitioners also report improvements in sleep disruption, irritability, and the general cluster of vasomotor symptoms that accompany declining estrogen levels. Metagenics positions it as an alternative for women who cannot or prefer not to use conventional hormone replacement therapy.
Dosage and How to Take It
The standard dose is one tablet daily, containing 4 mg of ERr 731 extract. Metagenics recommends taking it with food and a glass of water at the same time each day. Consistency matters: most women see some improvement within 4 weeks, but full benefit may take up to 3 months of daily use. If you stop taking it and symptoms return, that timeline resets.
What It Is Not
Estrovera is classified as a dietary supplement, not a drug. This distinction is important. The FDA does not review supplements for safety or efficacy before they reach store shelves the way it does for prescription medications. No FDA approval exists for ERr 731 as a treatment for menopause symptoms. The extract does not appear in the FDA’s public database of New Dietary Ingredient notifications, which is the formal process by which supplement companies notify the agency about novel ingredients.
It is also not a phytoestrogen in the way that soy isoflavones or red clover are. Those compounds tend to activate both estrogen receptor types with varying degrees of selectivity. ERr 731’s near-exclusive preference for the beta receptor puts it in a different pharmacological category, even though all of these are loosely grouped together as “plant-based estrogen alternatives.”
Safety Considerations
The selective receptor profile of ERr 731 suggests a favorable safety picture compared to conventional estrogen, particularly regarding breast tissue and the uterine lining. Because it does not activate estrogen receptor alpha in lab settings, the theoretical risk of stimulating hormone-sensitive tissues is low. Clinical trials have generally reported mild or no side effects, though large-scale, long-term safety data of the kind required for pharmaceutical drugs does not exist for this supplement.
For women with a history of hormone receptor-positive breast cancer, the picture is more nuanced. Systemic estrogen is generally considered contraindicated in this population due to the potential for increasing recurrence risk. While ERr 731’s beta-selective mechanism is different from systemic estrogen, no large trials have specifically studied its safety in breast cancer survivors. The American College of Obstetricians and Gynecologists notes that the effects of exogenous estrogens on breast tissue would be expected to be blocked in women taking tamoxifen but not in those taking aromatase inhibitors. Whether ERr 731’s beta selectivity changes this equation is not well established, so women with a history of hormone-sensitive cancer should discuss it with their oncologist before starting.
How It Compares to Hormone Therapy
Conventional hormone replacement therapy remains the most effective treatment for severe hot flashes, typically reducing their frequency by 75% or more. Estrovera is positioned as a milder, plant-based option for women with moderate symptoms, those who have contraindications to hormone therapy, or those who simply prefer a supplement-based approach. The 4 mg dose is extraordinarily small compared to standard estrogen prescriptions, which reflects its targeted mechanism rather than a systemic hormone effect.
The tradeoff is predictable: gentler mechanism, gentler results. Women with debilitating hot flashes dozens of times a day may find it insufficient. Women with moderate symptoms who want to avoid prescription hormones are the core audience. The 4-week to 3-month timeline for results also requires patience that isn’t necessary with hormone therapy, which typically works within days to weeks.